Alpha Innotech Reports Strong First Quarter International Revenue Growth

SAN LEANDRO, Calif., May 14, 2008 (BUSINESS WIRE) ----Alpha Innotech Corp. (OTCBB:APNO), a leading provider of bioanalytical systems for drug discovery and life science research, today reported financial results for the quarter ending March 31, 2008.

First quarter revenues of $3.668 million increased 3.4% from the $3.547 million reported in the same period in 2007.

The Company posted a net loss of $2,000 in the first quarter ending March 31, 2008 as compared to a $1,000 net loss in the comparable period of 2007.

Excluding stock-based compensation, interest, and depreciation on a non-GAAP basis, the Company had net income of $338,000 for the first quarter of 2008 compared to $280,000 for the first quarter of 2007. The non-GAAP net income (loss) is reconciled to comparable GAAP net income (loss) in the table entitled "Non-GAAP Calculation of Net Income (Loss)".

"Our focus on the rapidly growing Pacific Rim markets contributed to first quarter international revenues increasing nearly 33% from a year ago," said Ron Bissinger, Chief Executive Officer of Alpha Innotech. "We're also looking forward to introducing additional products in our second quarter that will continue our growth momentum."

Additional First Quarter 2008 Achievements

-- Posted seventh consecutive quarter with positive cash flows from operating activities

-- Began shipping red(TM), our personal gel imager combining touch screen controls with advanced imaging technology and an integrated onboard computer, all in a uniquely compact footprint

-- Added sales personnel in Shanghai and Singapore to strengthen the Company's presence in the rapidly growing Pacific Rim region

More information on Alpha Innotech can be found at the Company's website www.alphainnotech.com.

About Alpha Innotech Corp.

Founded in 1992 and with over 10,000 systems sold worldwide, Alpha Innotech is a leading developer, manufacturer and marketer of digital imaging and analysis systems for the life science research and drug discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide.

Use of Non-GAAP Financial Measures

To supplement the Company's financial statements presented in accordance with GAAP, the Company is also providing non-GAAP financial information. The presentation of non-GAAP financial information should be considered in addition to the Company's GAAP results and is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with GAAP. The Company believes that both management and investors benefit from referring to non-GAAP financial information that excludes certain expenses in their assessment of the Company's performance. The Company also believes that investors benefit from increased transparency into supplemental information used by management in its financial and operational decision making.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. These forward-looking statements involve a number of risks and uncertainties that include, but are not limited to, the Company's ability to obtain additional financing if needed, the timing of the introduction and success of new products, and the Company's growth prospects, that could cause actual results to differ materially from those anticipated or planned by these forward-looking statements. Please also refer to the risk factors described in our filings with the Securities and Exchange Commission, including our recent Form 10-KSB and Forms 10-QSB filed with the Securities and Exchange Commission. We do not intend to update the forward-looking information contained in this news release except as required by law.

 Alpha Innotech Corp. Condensed Consolidated Statements of Operations
   (in thousands, except per share amounts) Three Months Ended March 31, ------------------------- 2008 2007 -------------------------
   Revenue 3,668 3,547 Cost of goods sold 1,557 1,575 ------------ ------------ Gross profit 2,111 1,972 ------------ ------------
   Operating expenses: Sales and marketing 1,185 1,055 Research and development 375 304 General and administrative 567 532 ------------
   ------------ Total operating expenses 2,127 1,891 ------------ ------------ Profit (loss) from operations (16) 81 Interest
   expense (83) (82) Other income (expense), net 97 0 ------------ ------------ Net profit (loss) applicable to common stockholders
   (2) (1) ============ ============ Profit (loss) per common share - basic and diluted $ (0.00) $ (0.00) ============ ============
   Weighted average shares outstanding - basic and diluted 10,536,390 10,343,383 ============ ============ 

 Alpha
   Innotech Corp. Condensed Consolidated Balance Sheets (in thousands) December 31, March 31, 2008 2007 ---------------- ------------
   (Unaudited) Assets -------------------------------------- Current assets: Cash and cash equivalents 214 168 Restricted cash
   50 50 Accounts receivable, net 2,071 2,230 Inventory, net 1,248 1,006 Prepaid expenses and other current assets 144 219 ----------------
   ------------ Total current assets 3,727 3,673 Property and equipment, net 854 914 Other assets 90 90 ---------------- ------------
   Total assets 4,671 4,677 ================ ============ Liabilities and Stockholders' Deficit ---------------------------------------
   Current liabilities: Accounts payable 1,768 1,786 Accrued liabilities 1,278 1,330 Current portion of debt 1,128 1,407 Deferred
   revenue 1,013 1,027 Other liabilities 287 265 ---------------- ------------ Total current liabilities 5,474 5,815 Debt, net
   of current portion 313 308 ---------------- ------------ Total stockholders' deficit (1,116) (1,446) ---------------- ------------
   Total liabilities and stockholders' deficit 4,671 4,677 ================ ============ 

 Alpha Innotech Corp. Non-GAAP
   Calculation of Net Income (Loss) (Unaudited) (in thousands) Three Months Ended March 31, 2008 2007 ------ ------ Non-GAAP
   calculation of net income (loss) : GAAP net loss (2) (1) Interest 83 82 Depreciation 137 144 Stock-based compensation 120
   55 ------ ------ Non- GAAP basis income (loss) $ 338 $ 280 ====== ====== 

SOURCE: Alpha Innotech Corp.

Alpha
   Innotech Corp. Ron Bissinger, CEO, 510-483-9620 

Copyright Business Wire 2008